BNR — Burning Rock Biotech Balance Sheet
0.000.00%
- $62.59m
- -$17.62m
- CNY537.44m
- 68
- 59
- 36
- 54
Annual balance sheet for Burning Rock Biotech, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 411 | 2,263 | 1,497 | 908 | 629 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 209 | 147 | 158 | 170 | 168 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 707 | 2,524 | 1,821 | 1,259 | 884 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 89.3 | 111 | 406 | 300 | 144 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 848 | 2,663 | 2,279 | 1,587 | 1,040 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 164 | 242 | 372 | 411 | 263 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 212 | 242 | 433 | 429 | 272 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 636 | 2,421 | 1,845 | 1,158 | 768 |
Total Liabilities & Shareholders' Equity | 848 | 2,663 | 2,279 | 1,587 | 1,040 |
Total Common Shares Outstanding |